ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

CUSIP: 82835W108

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
+3,240,798
Put/Call ratio
48%
SEC-reported price per share
$6.51
Number of holders
88
Value change
+$19,586,591
Number of buys
59
Open additional details 1 more signal available
Number of sells
27
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
98,457,811

Security key

82835W108

Report period

Q1 2023

Institutions

88

Top holders

10

Ownership snapshot

Top reported holders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
DEERFIELD MANAGEMENT COMP...
Disclosed value leader
DEERFIELD MANAGEMENT COMP...
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F Highest disclosed value: $94,494,717 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

DEERFIELD MANAGEMENT COMPANY, L.P. has the largest disclosed position value at $94.49M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens DEERFIELD MANAGEMENT COMPANY, L.P.'s linked filing trail.
Disclosed position value Top 5
DEERFIELD MANAGEMENT COMPANY, L.P. $94.49M
ORBIMED ADVISORS LLC $74.56M
RA CAPITAL MANAGEMENT, L.P. $25.67M
SR ONE CAPITAL MANAGEMENT, LP $25.67M
Rubric Capital Management LP $25.51M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
DEERFIELD MANAGEMENT COMPANY, L.P.
13F
Company
13F
—
denominator unverified
$94,494,717
11,077,927 shares
— 31 Dec 2022
ORBIMED ADVISORS LLC
13F
Company
13F
—
denominator unverified
$74,559,766
8,740,887 shares
— 31 Dec 2022
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$25,672,553
3,009,678 shares
— 31 Dec 2022
SR ONE CAPITAL MANAGEMENT, LP
13F
Company
13F
—
denominator unverified
$25,672,544
3,009,677 shares
— 31 Dec 2022
Rubric Capital Management LP
13F
Company
13F
—
denominator unverified
$25,509,511
2,990,564 shares
— 31 Dec 2022
K2 PRINCIPAL FUND, L.P.
13F
Company
13F
—
denominator unverified
$24,499,422
2,872,148 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
88
Shares
53,405,274
Rows available
88
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders
88
Q1 2023 holders
88
Holder diff
0
Investor Q1 2023 Shares Q1 2023 Shares Share Diff Share Chg % Q1 2023 value Q1 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .